Resveratrol mit Piperin
In einer randomisierten kontrollierten Studie aus dem Jahr 2021 erhielten die Teilnehmer eine Einzeldosis Resveratrol von 2500 mg, mit Piperin in Dosen von 0 mg, 5 mg oder 25 mg. Trotz der Beobachtung, dass die Koadministration von Piperin die Bioverfügbarkeit (Cmax und AUC) von Resveratrol bei C57BL-Mäusen signifikant erhöht, konnte bei gesunden Erwachsenen, die 2500 mg Resveratrol mit Piperin (5 oder 25 mg) im Vergleich zu Resveratrol allein einnahmen, kein signifikanter Anstieg des Resveratrols oder eine Abnahme von Resveratrolglucuronid beobachtet werden. [1]
- ↑ Bailey HH et al.: A randomized, double-blind, dose-ranging, pilot trial of piperine with resveratrol on the effects on serum levels of resveratrol.
Eur J Cancer Prev
2021. (PMID 32868637)
[PubMed]
[DOI]
[Full text]
Abstract
Resveratrol (3,4,5-trihydroxystilbene) is a naturally occurring phytoalexin with purported health-promoting effects, but with limited oral bioavailability. Our prior murine modeling research observed enhanced resveratrol bioavailability with piperine co-administration. In this study, single-dose pharmacokinetics of resveratrol with or without piperine and the associated toxicities were studied on a cohort of healthy volunteers. We performed a double-blind, randomized, three-arm pilot study. Participants were randomized to receive a single dose of resveratrol 2.5 g, with piperine in 0 mg, 5 mg, or 25 mg dose. An improved liquid chromatography/mass spectrometry assay was used to determine serum levels of resveratrol and resveratrol-glucuronide. Baseline through 24 h post-study drug serum analyses were performed and adverse events were followed for 30 days. Twenty-four participants were enroled. No significant relationship between dose and pharmacokinetic values were found. In the sex stratified analysis, Cmax for resveratrol in women showed a trend (P = 0.057) toward an increase with piperine. Pharmacokinetic values for resveratrol were: Cmax - 18.5 ± 16 ng/mL resveratrol alone, 29 ± 29 resveratrol + 5 mg piperine, 16 ± 13 resveratrol + 25 mg piperine; area under the concentration × time curve - 1270 ± 852 ng/h/mL resveratrol alone, 2083 ± 2284 resveratrol + 5 mg piperine, 1132 ± 222 resveratrol + 25 mg piperine. All subjects tolerated their protocol therapy with minimal to no toxicity and no evidence of differences between the three groups. The co-administration of resveratrol with piperine at 5 and 25 mg doses did not sufficiently alter the pharmacokinetics of resveratrol or resveratrol-glucuronide to demonstrate the significant enhancement observed in murine modeling.
